A Phase II and Biomarker Study of Ramucirumab, a Human Monoclonal Antibody Targeting the VEGF Receptor-2, as First-Line Monotherapy in Patients with Advanced Hepatocellular Cancer

X. Zhu, Andrew; S. Finn, Richard; F. Mulcahy, Mary; Gurtler, Jayne; Sun, Weijing; D. Schwartz, Jonathan; P. Dalal, Rita; Joshi, Adarsh; R. Hozak, Rebecca; Xu, Yihuan; Ancukiewicz, Marek; K. Jain, Rakesh; Warren Nugent, F.; G. Duda, Dan; Stuart, Keith

doi:10.1158/1078-0432.ccr-13-1442

Public

A Phase II and Biomarker Study of Ramucirumab, a Human Monoclonal Antibody Targeting the VEGF Receptor-2, as First-Line Monotherapy in Patients with Advanced Hepatocellular Cancer

Published in Clinical Cancer Research • Oct 2, 2013

Authors:

Andrew X. Zhu

Richard S. Finn

Mary F. Mulcahy

Abstract

PURPOSE: To assess the efficacy and safety of the anti-VEGF receptor-2 (VEGFR-2) antibody ramucirumab as first-line therapy in patients with advanced hepatocellular carcinoma and explore potential circulating biomarkers. EXPERIMENTAL DESIGN: Adults with advanced hepatocellular carcinoma and no prior...

Subject

Ramucirumab

Medicine

Internal medicine

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!